Bio-Rad Labs (BIO) Stock
Key stats
- Market cap
- $10.26B
- Price / Earnings ratio
- 10.0x
- EPS (TTM)
- $37.88
- Volume
- Loading
- 52-week high
- $396.23
- 52-week low
- $236.73
- EPS vs analyst estimate
- +8.7%Q3 FY25 · $2.26 vs $2.08
Source: third-party data provider, as of November 10, 2026
EPS estimate: analyst consensus
Compare with BIO
Recent news
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
BIO
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
BIO
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
BIO
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIONews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 59.44
- MACD 12/26/9
- 3.21
- EMA 9 of MACD
- 1.56
- MACD histogram
- 1.64
- SMA 50
- $373.63
- Price above SMA 50
- EMA 50
- $367.83
- Price above EMA 50
- SMA 200
- $315.40
- Price above SMA 200
- EMA 200
- $329.24
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $2.62 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
BIOBio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
BIOBio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
BIOHere's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
BIO
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
BIO
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
BIO
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
BIO
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
BIO
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
BIONews tone: automated (AI) classification of the article's content, not a price prediction.
About Bio-Rad Labs
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Norman D. Schwartz | Chairman & CEO | 1950 |
| Mr. Jonathan P. DiVincenzo | President & COO | 1966 |
| Mr. Roop K. Lakkaraju CPA | Executive VP & CFO | 1971 |
| Mr. James J. Barry | Executive VP & President of Life Science Group | 1978 |
| Mr. Rajat Mehta | Executive Vice President of Global Commercial Operations | 1979 |
| Mr. Ruben Argueta | Vice President of Investor Relations | — |
| Matthew Werner | Senior VP and Chief Compliance & Privacy Officer | — |
| Ms. Courtney C. Enloe | Executive VP, General Counsel & Secretary | 1972 |
| Ms. Nanditha R. Yelamanchi | Executive Vice President of Global Human Resources | — |
| Mr. Michael Crowley | Executive Vice President of Global Commercial Operations | 1962 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 10, 2026
Technical indicators
- RSI 14
- 59.44
- MACD 12/26/9
- 3.21
- EMA 9 of MACD
- 1.56
- MACD histogram
- 1.64
- SMA 50
- $373.63
- Price above SMA 50
- EMA 50
- $367.83
- Price above EMA 50
- SMA 200
- $315.40
- Price above SMA 200
- EMA 200
- $329.24
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 9, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $440.00
- Average
- $440.00
- High
- $440.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.1 | +0.0 | ||||||||||
| 2022 | -18.5 | +2.6 | -8.7 | -10.3 | +7.3 | -6.2 | +12.1 | -12.4 | -14.2 | -17.8 | +15.7 | +0.6 |
| 2023 | +10.7 | +0.9 | +0.8 | -3.0 | -17.7 | +2.1 | +7.4 | -1.7 | -9.2 | -21.7 | +9.9 | +5.2 |
| 2024 | -2.2 | -0.9 | +4.1 | -20.4 | +4.7 | -5.5 | +28.2 | -1.2 | +0.1 | +6.1 | -7.6 | -3.0 |
| 2025 | +10.6 | -24.9 | -5.0 | +1.7 | -5.6 | +11.4 | -2.4 | +4.7 | -3.5 | +7.2 | +4.3 | -5.8 |
| 2026 | -3.8 | -6.4 | -0.3 | +0.6 | +21.8 | -3.9 | +9.6 | +15.4 | -0.9 | +4.7 | +6.0 |
